Science Explorer Back to mapMap

Most cited papers from Medpace (United States)

What are the most cited papers from Medpace (United States)?

The most cited paper from Medpace (United States) is "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial" (Kishore M. Gadde, David Blair Allison, Donna H. Ryan et al., 2011), with 1,062 citations. Next come "Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol" (1,000) and "Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia" (824).

Showing 50 of 59 papers. Every paper with more than 76 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial Kishore M. Gadde, David Blair Allison, Donna H. Ryan et al. · The Lancet Apr 2011 1,062
2 Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol Kausik Kumar Ray, Ulf Landmesser, Lawrence A. Leiter et al. · New England Journal of Medicine Open access 17 Mar 2017 1,000
3 Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia Frederick Johan Raal, David G. Kallend, Kausik Kumar Ray et al. · New England Journal of Medicine Open access 18 Mar 2020 824
4 Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial Stephen A. Harrison, Mustafa Rifaat Bashir, Cynthia D. Guy et al. · The Lancet Nov 2019 794
5 Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP) David Blair Allison, Kishore M. Gadde, William Timothy Garvey et al. · Obesity Open access 3 Nov 2011 725
6 Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study William Timothy Garvey, Donna H. Ryan, Michelle Look et al. · American Journal of Clinical Nutrition Open access 8 Dec 2011 715
7 A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis Scott L. Friedman et al. · Hepatology Open access 17 Aug 2017 676
8 Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol Evan A. Stein, Scott J. Mellis, George D. Yancopoulos et al. · New England Journal of Medicine Open access 22 Mar 2012 673
9 The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans Michael Walter Weiner, Paul S. S Aisen, Clifford R. Jack et al. · Alzheimer s & Dementia Open access May 2010 617
10 Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy James M. McKenney, Michael J. Koren, Dean J. Kereiakes et al. · Journal of the American College of Cardiology Open access 28 Mar 2012 514
11 Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia Eli M. Roth, James M. McKenney, Corinne Hanotin et al. · New England Journal of Medicine Open access 31 Oct 2012 470
12 Associations Between Screen-Based Media Use and Brain White Matter Integrity in Preschool-Aged Children John Hutton, Jonathan A. Dudley, Tzipi Horowitz‐Kraus et al. · Archives of Pediatrics and Adolescent Medicine Open access 4 Nov 2019 468
13 Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension Mason Wright Freeman, Yuan‐Di C. Halvorsen, William Marshall et al. · New England Journal of Medicine Open access 7 Nov 2022 384
14 Pharmacokinetics and Pharmacodynamics of Recombinant Human Angiotensin-Converting Enzyme 2 in Healthy Human Subjects Manuel Haschke, Manfred Schuster, Marko Poglitsch et al. · Clinical Pharmacokinetics 16 May 2013 381
15 Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial David Charles Hess, Lawrence R. Wechsler, Wayne M. Clark et al. · The Lancet Neurology 17 Mar 2017 377
16 Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial Stephen A. Harrison, Peter Jerome Ruane, Bradley L. Freilich et al. · Nature Medicine Jul 2021 363
17 Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial) Harold Edward Bays, Christie Mitchell Ballantyne, John J.P. Kastelein et al. · The American Journal of Cardiology 22 Jun 2011 356
18 Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study) Christie Mitchell Ballantyne, Harold Edward Bays, John J.P. Kastelein et al. · The American Journal of Cardiology 20 Jul 2012 344
19 OpenFold: retraining AlphaFold2 yields new insights into its learning mechanisms and capacity for generalization Gustaf Ahdritz et al. · Nature Methods Open access 14 May 2024 331
20 Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes Catherine C. Robertson et al. · Nature Genetics 14 Jun 2021 308
21 Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels Steven E. Nissen, Kathy Wolski, Craig Balog et al. · JAMA Open access 3 Apr 2022 300
22 De novo design of modular and tunable protein biosensors Alfredo Quijano‐Rubio, Andy Hsien-Wei Yeh, Jooyoung Park et al. · Nature Open access 27 Jan 2021 277
23 Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study Lynne E. Wagenknecht, Jean M. Lawrence, Scott P. Isom et al. · The Lancet Diabetes & Endocrinology Open access 28 Feb 2023 258
24 We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine Kathryn M. Lemberg, James J. Vornov, Rana Rais et al. · Molecular Cancer Therapeutics Open access Sep 2018 256
25 The efficacy of a brief app-based mindfulness intervention on psychosocial outcomes in healthy adults: A pilot randomised controlled trial Louise Champion, Marcos Economides, Chris Chandler · PLoS ONE Open access 31 Dec 2018 246
26 Standardization of analysis sets for reporting results from ADNI MRI data Bradley T. Wyman et al. · Alzheimer s & Dementia Open access 27 Oct 2012 240
27 Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease Clifford R. Jack et al. · Alzheimer s & Dementia Open access Jul 2011 225
28 Machine learning for comprehensive forecasting of Alzheimer’s Disease progression Charles K. Fisher et al. · Scientific Reports Open access 20 Sep 2019 223
29 Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes Matthew C. Riddle, Guillermo E. Umpierrez, ANDRES G. DIGENIO et al. · Diabetes Care Open access 26 Oct 2011 219
30 Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release William Timothy Garvey, Donna H. Ryan, Robert R. Henry et al. · Diabetes Care Open access 9 Oct 2013 215
31 Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors Aditya Bagrodia et al. · Journal of Clinical Oncology Open access 20 Sep 2016 206
32 Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH Stephen A. Harrison, Mustafa Rifaat Bashir, Sam E. Moussa et al. · Hepatology Communications Open access 4 Jan 2021 195
33 Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial Stephen James Nicholls, Marc Ditmarsch, John J.P. Kastelein et al. · Nature Medicine Open access Aug 2022 174
34 Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds Sotirios Tsimikas, Santica M. Marcovina · Journal of the American College of Cardiology Open access Aug 2022 150
35 Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus Deepak L. Bhatt, Tilo Großer, Jing-fei Dong et al. · Journal of the American College of Cardiology Open access 11 Jan 2017 149
36 Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance Paul Daniel Thompson, Diane Elaine MacDougall, Roger S. Newton et al. · Journal of clinical lipidology Open access 6 Jan 2016 147
37 The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel Paul Alfred Gurbel, Kevin P. Bliden, Douglas K. Logan et al. · Journal of the American College of Cardiology Open access 17 Apr 2013 139
38 Azithromycin Polarizes Macrophages to an M2 Phenotype via Inhibition of the STAT1 and NF-κB Signaling Pathways Dalia Haydar, Theodore James Cory, Susan E. Birket et al. · The Journal of Immunology Open access Jul 2019 135
39 Multiplatform molecular test performance in indeterminate thyroid nodules Mark Armin Lupo, Ann E. Walts, John Woody Sistrunk et al. · Diagnostic Cytopathology Open access 7 Aug 2020 117
40 Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease Matthew J. Price, James S. Walder, Brian Baker et al. · Journal of the American College of Cardiology Open access Jun 2012 117
41 Lp(a): When and how to measure it Jaimini Cegla, Michael W. France, Santica M. Marcovina et al. · Annals of Clinical Biochemistry International Journal of Laboratory Medicine Open access 12 Oct 2020 114
42 A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis Stephen A. Harrison, Peter Jerome Ruane, Bradley L. Freilich et al. · JHEP Reports Open access 23 Aug 2022 107
43 A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer Miklos Pless, C. Droege, Roger von Moos et al. · Lung Cancer 23 Jul 2013 107
44 A Highly Bioavailable Omega-3 Free Fatty Acid Formulation Improves the Cardiovascular Risk Profile in High-Risk, Statin-Treated Patients With Residual Hypertriglyceridemia (the ESPRIT Trial) Kevin Carl Maki, David G. Orloff, Stephen James Nicholls et al. · Clinical Therapeutics 30 Aug 2013 105
45 Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk Stephen James Nicholls et al. · New England Journal of Medicine Open access 7 May 2025 99
46 Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas et al. · Clinical Gastroenterology and Hepatology Open access 4 Mar 2024 99
47 Recent advances in electrogenerated chemiluminescence biosensing methods for pharmaceuticals Yu Zhang, Rui Zhang, Xiaolin Yang et al. · Journal of Pharmaceutical Analysis Open access 22 Nov 2018 97
48 Early human impacts and ecosystem reorganization in southern-central Africa Jessica C. Thompson et al. · Science Advances Open access 5 May 2021 91
49 Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics Evan A. Stein, Gary D. Swergold · Current Atherosclerosis Reports 31 Jan 2013 85
50 Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer Jerry R. Colca, James T. VanderLugt, Wade J. Adams et al. · Clinical Pharmacology & Therapeutics Open access 18 Jan 2013 84

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.